The Frequency of Intestinal Parasitic Infections in COVID-19 Patients: A Case-Control Study in Tehran, Capital of Iran

Table 2

Age, gender, type of stool, diarrhea status, residence, type of patients, lung complications, and duration of treatment of patients with COVID-19 and healthy group, according to the presence or absence of intestinal parasites.

Variables	COVID-19 patients (n = 200)				Healthy group (n = 200)
	No. of examined	No. of positive (%)	No. of negative (%)	value	No. of examined	No. of positive (%)	No. of negative (%)	value
Age group (year)
20–30	20 (10%)	1 (5%)	19 (95%)	0.65	18 (9%)	0 (0%)	18 (100%)	0.71
31–40	44 (22%)	5 (11.37%)	39 (88.63%)		44 (22%)	4 (9.09%)	40 (90.91%)
41–50	52 (26%)	6 (11.54%)	46 (88.46%)		48 (24%)	6 (12.5%)	42 (87.5%)
51–60	51 (25.5%)	10 (19.60%)	41 (80.40%)		64 (32%)	4 (6.25%)	60 (93.75%)
61–70	33 (16.5%)	4 (12.12%)	29 (87.88%)		26 (13%)	1 (3.84%)	25 (96.16%)
Sex
Male	107 (53.5%)	16 (14.95%)	91 (85.05%)	0.53	102 (51%)	9 (8.82%)	93 (91.18%)	0.50
Female	93 (46.5%)	10 (10.75%)	83 (89.25%)		98 (49%)	6 (6.12%)	92 (93.88%)
Residence
Urban	151 (75.5%)	16 (10.60%)	135 (89.40%)	0.21	145 (72.5%)	10 (6.90%)	135 (93.10%)	0.62
Rural	49 (24.5%)	10 (20.40%)	39 (79.60%)		55 (27.5%)	5 (9.10%)	50 (90.90%)
Type of stool
Formed	61 (30.5%)	1 (1.64%)	60 (98.36%)	<	71 (35.5%)	4 (5.63%)	67 (94.37%)	0.87
Soft	101 (50.5%)	9 (8.91%)	92 (91.09%)		99 (49.5%)	9 (9.09%)	90 (90.91%)
Loose	18 (9%)	7 (38.88%)	11 (61.12%)		17 (8.5%)	1 (5.88%)	16 (94.12%)
Watery	20 (10%)	9 (45%)	11 (55%)		13 (6.5%)	1 (7.69%)	12 (92.31%)
Diarrhea
Yes	38 (19%)	16 (42.10%)	22 (57.90%)	<	30 (15%)	2 (6.66%)	28 (93.34%)	0.86
No	162 (81%)	10 (6.17%)	152 (93.83%)		170 (85%)	13 (7.64%)	157 (92.36%)
Duration of treatment of patients with COVID-19
2 weeks	61 (30.5%)	4 (6.55%)	57 (93.45%)	0.10	—	—	—	—
2–4 weeks	43 (21.5%)	4 (9.30%)	39 (90.70%)		—	—	—	—
4–6 weeks	25 (12.5%)	3 (12%)	22 (88%)		—	—	—	—
6 weeks<	71 (35.5%)	15 (21.12%)	56 (78.88%)		—	—	—	—
Type of patients
Inpatients	109 (54.5%)	15 (13.76%)	94 (86.24%)	0.55	—	—	—	—
Outpatients	91 (45.5%)	11 (12.09%)	80 (87.91%)		—	—	—	—
Lung complications
25%>	49 (24.5%)	6 (12.24%)	43 (87.76%)	0.77	—	—	—	—
25–49%	42 (21%)	5 (11.90%)	37 (88.10%)		—	—	—	—
50%≤	109 (54.5%)	15 (13.76%)	94 (86.24%)		—	—	—	—

values <0.05 are statistically significant.